Limits...
Priming Mesenchymal Stem Cells with Endothelial Growth Medium Boosts Stem Cell Therapy for Systemic Arterial Hypertension.

de Oliveira LF, Almeida TR, Ribeiro Machado MP, Cuba MB, Alves AC, da Silva MV, Rodrigues Júnior V, Dias da Silva VJ - Stem Cells Int (2015)

Bottom Line: Priming of the MSCs reduced the basal cell death rate in vitro.The administration of pMSCs significantly induced a prolonged reduction (10 days) in arterial pressure, a decrease in cardiac hypertrophy, an improvement in endothelium-dependent vasodilation response to acetylcholine, and an increase in skeletal muscle microvascular density compared to the vehicle and MSC groups.The transplanted cells were rarely found in the hearts and kidneys.

View Article: PubMed Central - PubMed

Affiliation: Physiology Division, Natural and Biological Sciences Institute, Triangulo Mineiro Federal University, 38025-015 Uberaba, MG, Brazil.

ABSTRACT
Systemic arterial hypertension (SAH), a clinical syndrome characterized by persistent elevation of arterial pressure, is often associated with abnormalities such as microvascular rarefaction, defective angiogenesis, and endothelial dysfunction. Mesenchymal stem cells (MSCs), which normally induce angiogenesis and improve endothelial function, are defective in SAH. The central aim of this study was to evaluate whether priming of MSCs with endothelial growth medium (EGM-2) increases their therapeutic effects in spontaneously hypertensive rats (SHRs). Adult female SHRs were administered an intraperitoneal injection of vehicle solution (n = 10), MSCs cultured in conventional medium (DMEM plus 10% FBS, n = 11), or MSCs cultured in conventional medium followed by 72 hours in EGM-2 (pMSC, n = 10). Priming of the MSCs reduced the basal cell death rate in vitro. The administration of pMSCs significantly induced a prolonged reduction (10 days) in arterial pressure, a decrease in cardiac hypertrophy, an improvement in endothelium-dependent vasodilation response to acetylcholine, and an increase in skeletal muscle microvascular density compared to the vehicle and MSC groups. The transplanted cells were rarely found in the hearts and kidneys. Taken together, our findings indicate that priming of MSCs boosts stem cell therapy for the treatment of SAH.

No MeSH data available.


Related in: MedlinePlus

Analysis of cardiac hypertrophy. (a) Values of body weight (g), (b) cardiac weight (mg), and (c) cardiac/body weight ratio (mg/g). Values indicated as the mean ± sem. ∗p < 0.05 versus saline.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4537741&req=5

fig5: Analysis of cardiac hypertrophy. (a) Values of body weight (g), (b) cardiac weight (mg), and (c) cardiac/body weight ratio (mg/g). Values indicated as the mean ± sem. ∗p < 0.05 versus saline.

Mentions: Consistent with arterial blood pressure reduction, treatment with MSCs primed with EGM-2 reduced cardiac hypertrophy, based on the cardiac weight to body weight ratio, compared with saline (3.95 ± 0.35 versus 4.36 ± 0.38, p < 0.05), but not compared with the MSC group (3.95 ± 0.35 versus 4.09 ± 0.26, p = nonsignificant). There were no differences in body weight and absolute heart weight among the three groups (Figure 5).


Priming Mesenchymal Stem Cells with Endothelial Growth Medium Boosts Stem Cell Therapy for Systemic Arterial Hypertension.

de Oliveira LF, Almeida TR, Ribeiro Machado MP, Cuba MB, Alves AC, da Silva MV, Rodrigues Júnior V, Dias da Silva VJ - Stem Cells Int (2015)

Analysis of cardiac hypertrophy. (a) Values of body weight (g), (b) cardiac weight (mg), and (c) cardiac/body weight ratio (mg/g). Values indicated as the mean ± sem. ∗p < 0.05 versus saline.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4537741&req=5

fig5: Analysis of cardiac hypertrophy. (a) Values of body weight (g), (b) cardiac weight (mg), and (c) cardiac/body weight ratio (mg/g). Values indicated as the mean ± sem. ∗p < 0.05 versus saline.
Mentions: Consistent with arterial blood pressure reduction, treatment with MSCs primed with EGM-2 reduced cardiac hypertrophy, based on the cardiac weight to body weight ratio, compared with saline (3.95 ± 0.35 versus 4.36 ± 0.38, p < 0.05), but not compared with the MSC group (3.95 ± 0.35 versus 4.09 ± 0.26, p = nonsignificant). There were no differences in body weight and absolute heart weight among the three groups (Figure 5).

Bottom Line: Priming of the MSCs reduced the basal cell death rate in vitro.The administration of pMSCs significantly induced a prolonged reduction (10 days) in arterial pressure, a decrease in cardiac hypertrophy, an improvement in endothelium-dependent vasodilation response to acetylcholine, and an increase in skeletal muscle microvascular density compared to the vehicle and MSC groups.The transplanted cells were rarely found in the hearts and kidneys.

View Article: PubMed Central - PubMed

Affiliation: Physiology Division, Natural and Biological Sciences Institute, Triangulo Mineiro Federal University, 38025-015 Uberaba, MG, Brazil.

ABSTRACT
Systemic arterial hypertension (SAH), a clinical syndrome characterized by persistent elevation of arterial pressure, is often associated with abnormalities such as microvascular rarefaction, defective angiogenesis, and endothelial dysfunction. Mesenchymal stem cells (MSCs), which normally induce angiogenesis and improve endothelial function, are defective in SAH. The central aim of this study was to evaluate whether priming of MSCs with endothelial growth medium (EGM-2) increases their therapeutic effects in spontaneously hypertensive rats (SHRs). Adult female SHRs were administered an intraperitoneal injection of vehicle solution (n = 10), MSCs cultured in conventional medium (DMEM plus 10% FBS, n = 11), or MSCs cultured in conventional medium followed by 72 hours in EGM-2 (pMSC, n = 10). Priming of the MSCs reduced the basal cell death rate in vitro. The administration of pMSCs significantly induced a prolonged reduction (10 days) in arterial pressure, a decrease in cardiac hypertrophy, an improvement in endothelium-dependent vasodilation response to acetylcholine, and an increase in skeletal muscle microvascular density compared to the vehicle and MSC groups. The transplanted cells were rarely found in the hearts and kidneys. Taken together, our findings indicate that priming of MSCs boosts stem cell therapy for the treatment of SAH.

No MeSH data available.


Related in: MedlinePlus